QQQ   443.00 (+0.91%)
AAPL   178.03 (-1.50%)
MSFT   412.80 (-0.20%)
META   499.66 (+1.94%)
GOOGL   137.49 (-0.70%)
AMZN   177.80 (+0.59%)
TSLA   199.88 (-0.99%)
NVDA   815.97 (+3.14%)
NIO   5.79 (+0.70%)
AMD   198.80 (+3.26%)
BABA   74.82 (+1.07%)
T   16.96 (+0.18%)
F   12.53 (+0.72%)
MU   95.54 (+5.44%)
CGC   3.28 (-0.30%)
GE   158.50 (+1.03%)
DIS   111.39 (-0.17%)
AMC   4.48 (+3.70%)
PFE   26.57 (+0.04%)
PYPL   61.26 (+1.52%)
XOM   106.22 (+1.63%)
QQQ   443.00 (+0.91%)
AAPL   178.03 (-1.50%)
MSFT   412.80 (-0.20%)
META   499.66 (+1.94%)
GOOGL   137.49 (-0.70%)
AMZN   177.80 (+0.59%)
TSLA   199.88 (-0.99%)
NVDA   815.97 (+3.14%)
NIO   5.79 (+0.70%)
AMD   198.80 (+3.26%)
BABA   74.82 (+1.07%)
T   16.96 (+0.18%)
F   12.53 (+0.72%)
MU   95.54 (+5.44%)
CGC   3.28 (-0.30%)
GE   158.50 (+1.03%)
DIS   111.39 (-0.17%)
AMC   4.48 (+3.70%)
PFE   26.57 (+0.04%)
PYPL   61.26 (+1.52%)
XOM   106.22 (+1.63%)
QQQ   443.00 (+0.91%)
AAPL   178.03 (-1.50%)
MSFT   412.80 (-0.20%)
META   499.66 (+1.94%)
GOOGL   137.49 (-0.70%)
AMZN   177.80 (+0.59%)
TSLA   199.88 (-0.99%)
NVDA   815.97 (+3.14%)
NIO   5.79 (+0.70%)
AMD   198.80 (+3.26%)
BABA   74.82 (+1.07%)
T   16.96 (+0.18%)
F   12.53 (+0.72%)
MU   95.54 (+5.44%)
CGC   3.28 (-0.30%)
GE   158.50 (+1.03%)
DIS   111.39 (-0.17%)
AMC   4.48 (+3.70%)
PFE   26.57 (+0.04%)
PYPL   61.26 (+1.52%)
XOM   106.22 (+1.63%)
QQQ   443.00 (+0.91%)
AAPL   178.03 (-1.50%)
MSFT   412.80 (-0.20%)
META   499.66 (+1.94%)
GOOGL   137.49 (-0.70%)
AMZN   177.80 (+0.59%)
TSLA   199.88 (-0.99%)
NVDA   815.97 (+3.14%)
NIO   5.79 (+0.70%)
AMD   198.80 (+3.26%)
BABA   74.82 (+1.07%)
T   16.96 (+0.18%)
F   12.53 (+0.72%)
MU   95.54 (+5.44%)
CGC   3.28 (-0.30%)
GE   158.50 (+1.03%)
DIS   111.39 (-0.17%)
AMC   4.48 (+3.70%)
PFE   26.57 (+0.04%)
PYPL   61.26 (+1.52%)
XOM   106.22 (+1.63%)
NASDAQ:ATRA

Atara Biotherapeutics (ATRA) Stock Price, News & Analysis

$0.80
+0.02 (+3.05%)
(As of 11:16 AM ET)
Today's Range
$0.76
$0.83
50-Day Range
$0.44
$1.22
52-Week Range
$0.20
$3.80
Volume
1.15 million shs
Average Volume
3.53 million shs
Market Capitalization
$81.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$28.00

Atara Biotherapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
3,499.0% Upside
$28.00 Price Target
Short Interest
Bearish
10.67% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.87
Upright™ Environmental Score
News Sentiment
0.04mentions of Atara Biotherapeutics in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.62) to ($1.78) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.13 out of 5 stars

Medical Sector

179th out of 957 stocks

Biological Products, Except Diagnostic Industry

25th out of 160 stocks


ATRA stock logo

About Atara Biotherapeutics Stock (NASDAQ:ATRA)

Atara Biotherapeutics, Inc. develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA2271 and ATA3271 to treat mesothelin; and ATA3219 for the treatment of B-cell malignancies, as well as ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. The company was incorporated in 2012 and is headquartered in Thousand Oaks, California.

ATRA Stock Price History

ATRA Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Atara Biotherapeutics Inc (ATRA)
The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
Atara Biotherapeutics, Inc. (0HIY.L)
Seth Klarman's Exit from Atara Biotherapeutics Inc
Atara Biotherapeutics Inc ATRA
See More Headlines
Receive ATRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Atara Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/01/2023
Today
3/01/2024
Next Earnings (Estimated)
3/06/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:ATRA
Fax
N/A
Employees
334
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$28.00
High Stock Price Target
$28.00
Low Stock Price Target
$28.00
Potential Upside/Downside
+3,499.0%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
3 Analysts

Profitability

Net Income
$-228,300,000.00
Net Margins
-6,390.31%
Pretax Margin
-6,390.18%

Debt

Sales & Book Value

Annual Sales
$63.57 million
Book Value
$1.33 per share

Miscellaneous

Free Float
97,336,000
Market Cap
$79.29 million
Optionable
Optionable
Beta
0.64
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Pascal Touchon D.V.M. (Age 61)
    President, CEO & Director
    Comp: $1.08M
  • Mr. K. Amar MuruganMr. K. Amar Murugan (Age 48)
    Executive VP & Chief Legal Officer
    Comp: $618.52k
  • Mr. Eric Hyllengren (Age 49)
    Senior VP & CFO
  • Dr. Anhco Nguyen Ph.D. (Age 51)
    Executive VP and Chief Scientific & Technical Officer
  • Alex Chapman
    Vice President of Corporate Communications & Investor Relations
  • Ms. Jill Henrich (Age 61)
    Executive VP and Global Head of Regulatory Affairs & Quality
  • Mr. Dan Maziasz
    Executive VP & Chief Business Officer














ATRA Stock Analysis - Frequently Asked Questions

Should I buy or sell Atara Biotherapeutics stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Atara Biotherapeutics in the last year. There are currently 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ATRA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ATRA, but not buy additional shares or sell existing shares.
View ATRA analyst ratings
or view top-rated stocks.

What is Atara Biotherapeutics' stock price target for 2024?

3 equities research analysts have issued 12-month price targets for Atara Biotherapeutics' shares. Their ATRA share price targets range from $28.00 to $28.00. On average, they anticipate the company's stock price to reach $28.00 in the next year. This suggests a possible upside of 3,499.0% from the stock's current price.
View analysts price targets for ATRA
or view top-rated stocks among Wall Street analysts.

How have ATRA shares performed in 2024?

Atara Biotherapeutics' stock was trading at $0.5128 at the start of the year. Since then, ATRA stock has increased by 51.7% and is now trading at $0.7780.
View the best growth stocks for 2024 here
.

Are investors shorting Atara Biotherapeutics?

Atara Biotherapeutics saw a increase in short interest in the month of February. As of February 15th, there was short interest totaling 10,870,000 shares, an increase of 44.4% from the January 31st total of 7,530,000 shares. Based on an average daily trading volume, of 3,690,000 shares, the days-to-cover ratio is presently 2.9 days.
View Atara Biotherapeutics' Short Interest
.

When is Atara Biotherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 6th 2024.
View our ATRA earnings forecast
.

How were Atara Biotherapeutics' earnings last quarter?

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) announced its quarterly earnings results on Wednesday, November, 1st. The biotechnology company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.63) by $0.03. The biotechnology company earned $2.14 million during the quarter, compared to the consensus estimate of $2.20 million. Atara Biotherapeutics had a negative trailing twelve-month return on equity of 783.31% and a negative net margin of 6,390.31%.

What is Pascal Touchon's approval rating as Atara Biotherapeutics' CEO?

38 employees have rated Atara Biotherapeutics Chief Executive Officer Pascal Touchon on Glassdoor.com. Pascal Touchon has an approval rating of 60% among the company's employees. This puts Pascal Touchon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 88.0% of employees surveyed would recommend working at Atara Biotherapeutics to a friend.

What other stocks do shareholders of Atara Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Atara Biotherapeutics investors own include CRISPR Therapeutics (CRSP), AbbVie (ABBV), Exelixis (EXEL), Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), OPKO Health (OPK), Gilead Sciences (GILD), Micron Technology (MU) and Pfizer (PFE).

Who are Atara Biotherapeutics' major shareholders?

Atara Biotherapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (6.56%), UBS Group AG (3.62%), Northern Trust Corp (0.83%), GSA Capital Partners LLP (0.77%), Charles Schwab Investment Management Inc. (0.73%) and Goldman Sachs Group Inc. (0.57%). Insiders that own company stock include Amar Murugan, Anhco Nguyen, Carol Giltner Gallagher, Eric J Hyllengren, Jakob Dupont, Joe Newell, Kristin Yarema, Matthew K Fust, Pascal Touchon, Thomas Peterffy, Utpal Koppikar and William K Heiden.
View institutional ownership trends
.

How do I buy shares of Atara Biotherapeutics?

Shares of ATRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ATRA) was last updated on 3/1/2024 by MarketBeat.com Staff